Multiple Myeloma: all 3,713 studies
Page 18 of 38. Open to participants first (754), then studies with results posted, then the rest; newest registration first within each.
- Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.Active, not recruitingNCT06479954
- Telehealth-based Symptom Management for Veterans Treated With SelinexorActive, not recruitingNCT06452446
- A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06425991Phase 1
- Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCompletedNCT06425276Phase 4
- Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot StudyCompletedNCT06418750Not applicable
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06413498Phase 3
- A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients with Refractory and Relapsing Multiple Myeloma Expressing Somatostatin ReceptorsWithdrawnNCT06411301Phase 1
- Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
- Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaActive, not recruitingNCT06381141Phase 1
- An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple MyelomaStatus unknownNCT06379451Early Phase 1
- Cohort Construction and Prognostic Model Construction for Multiple MyelomaActive, not recruitingNCT06366802
- A Real-World Study of Bispecific Antibodies in Multiple MyelomaCompletedNCT06359067
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06353022Phase 2
- Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnNCT06352866Phase 2
- Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
- Precision Medicine StudyCompletedNCT06338150
- Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell TransplantationActive, not recruitingNCT06328699Not applicable
- SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDSActive, not recruitingNCT06325748Phase 1
- Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe NeutropeniaActive, not recruitingNCT06323447
- PatIent exPeRiences and prEFerence of trEatment foR Multiple MyelomaCompletedNCT06322927
- Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT06304636Phase 1
- Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug ClassesActive, not recruitingNCT06282978Phase 2
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT06232707Phase 3
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple MyelomaSuspendedNCT06232044Phase 1/2
- Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06223516Phase 1
- Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06216158Phase 3
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Active, not recruitingNCT06215118Phase 1
- Selinexor, Cyclophosphamide and Prednisone in MyelomaCompletedNCT06212596Phase 2
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
- Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMMActive, not recruitingNCT06205823
- Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT06203912Phase 1
- Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedNCT06179888Phase 2
- MMRC Horizon One: RRMM (MMRC-099)Active, not recruitingNCT06171685Phase 2
- Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple MyelomaCompletedNCT06170151
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06169215Phase 2
- A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT06163898Phase 1
- A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanCompletedNCT06163040
- Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory DrugsCompletedNCT06160167
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
- Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelActive, not recruitingNCT06154902
- A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple MyelomaCompletedNCT06151717
- A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell DisordersActive, not recruitingNCT06126341
- Multiple Myeloma Prognostic IndicesCompletedNCT06095752
- Study of BEBT-908 in Subjects With Advanced Hematological TumorsCompletedNCT06082596Phase 1
- Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple MyelomaActive, not recruitingNCT06073353Not applicable
- Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With LenalidomideCompletedNCT06069024
- Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple MyelomaTerminatedNCT06068400Not applicable
- Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma PatientsActive, not recruitingNCT06062537
- Multiple Myeloma Yoga Pilot StudyCompletedNCT06061302Not applicable
- Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT06050512Phase 1/2
- A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationActive, not recruitingNCT06045806Phase 3
- MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
- Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple MyelomaCompletedNCT06041698Not applicable
- Alvocade® (Bortezomib) Safety and Effectiveness StudyCompletedNCT06012383
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingNCT05981209Phase 1
- An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaWithdrawnNCT05980507Phase 1
- Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
- Providing Cancer Care Closer to Home for Patients With Multiple MyelomaTerminatedNCT05971056Not applicable
- A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple MyelomaActive, not recruitingNCT05955508Phase 2
- Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05954780
- CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT05950113Phase 1
- Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCTCompletedNCT05928156Not applicable
- mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT05918250Phase 1
- Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple MyelomaCompletedNCT05918185
- Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05908396Phase 1
- SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Phase 1
- Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple MyelomaActive, not recruitingNCT05889221Not applicable
- Corneal Toxicity in Patients Treated by Belantamab MafodotinCompletedNCT05887206
- A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory MyelomaWithdrawnNCT05874193Phase 2
- Integrated Actionable Aging Assessment for Cancer Patients PilotActive, not recruitingNCT05871008Not applicable
- A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple MyelomaActive, not recruitingNCT05860036Phase 2
- A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 AbnormalitiesActive, not recruitingNCT05850286Phase 2
- BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCTWithdrawnNCT05846737Phase 2
- Biomarker for Infection Risk in CLL and MMActive, not recruitingNCT05844033
- The Effect of Self Acupressure Application on Pain, Fatigue and Sleep Quality in Multiple Myeloma PatientsCompletedNCT05842265Not applicable
- A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)TerminatedNCT05839626Phase 1
- Study of CT071 Injection in RRMM or PPCLActive, not recruitingNCT05838131Early Phase 1
- Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.CompletedNCT05835726
- Corneal Findings in Patients Treated With Belantamab MafodotinTerminatedNCT05833737
- Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation ProgramActive, not recruitingNCT05831358Not applicable
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05827016Phase 3
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
- Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplantWithdrawnNCT05820763Phase 2
- Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
- The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma PatientsStatus unknownNCT05802992Phase 3
- Cevostamab Following CAR T Cell Therapy for RRMMActive, not recruitingNCT05801939Phase 2
- Optical Genome Mapping in Characterization of Multiple MyelomaCompletedNCT05786105
- A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisActive, not recruitingNCT05775094Phase 1
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingNCT05767359Phase 2
- Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaApproved for marketingNCT05757973
- A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesCompletedNCT05742217
- AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaStatus unknownNCT05740891Phase 1
- Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple MyelomaCompletedNCT05724966
- The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based MetabolomicsStatus unknownNCT05718401
- Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma ProgressionCompletedNCT05712967
- A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaStatus unknownNCT05712083Phase 2